{
  "url": "https://openlegislation.uk/eu-regulation-2017-1510/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2017-1510/annex.json",
  "legislation": "eur/2017/1510",
  "legislation_title": "Commission Regulation (EU) 2017/1510 of 30 August 2017 amending the Appendices to Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards CMR substances (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2017-1510",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Annex XVII to Regulation (EC) No 1907/2006 is amended as follows:\n(1) in Appendix 2, the following entries are inserted in the table in order of the index numbers set out therein:\n‘\n1,2-dichloropropane; propylene dichloride\n602-020-00-0\n201-152-2\n78-87-5\ne-glass microfibers of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]\n014-046-00-4\n—\n—\n’\n(2) in Appendix 4, the following entry is inserted in the table in order of the index number set out therein:\n‘\n3,7-dimethylocta-2,6-dienenitrile\n608-067-00-3\n225-918-0\n5146-66-7\n’\n(3) in Appendix 5,\n(a) the following entries are inserted in the table in order of the index numbers set out therein:\n‘\nbrodifacoum (ISO);\n4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin\n607-172-00-1\n259-980-5\n56073-10-0\nlead powder;\n[particle diameter < 1 mm]\n082-013-00-1\n231-100-4\n7439-92-1\nlead massive:\n[particle diameter ≥ 1 mm]\n082-014-00-7\n231-100-4\n7439-92-1\n’\n(b) the entry relating to warfarin; 4-hydroxy-3-(3-oxo-1- phenylbutyl)-coumarin is replaced by the following entry:\n‘\nwarfarin (ISO);\n4-hydroxy-3-(3-oxo-1- phenylbutyl)-2H-chromen-2-one; [1]\n(S)-4-hydroxy-3-(3-oxo- 1-phenylbutyl)-2-benzopyrone; [2]\n(R)-4-hydroxy-3-(3-oxo- 1-phenylbutyl)-2-benzopyrone [3]\n607-056-00-0\n201-377-6 [1]\n226-907-3 [2]\n226-908-9 [3]\n81-81-2 [1]\n5543-57-7 [2]\n5543-58-8 [3]\n’\n(4) in Appendix 6,\n(a) the following entries are inserted in the table in order of the index numbers set out therein:\n‘\ntetrahydro-2-furyl-methanol; tetrahydrofurfuryl alcohol\n603-061-00-7\n202-625-6\n97-99-4\ngallium arsenide\n031-001-00-4\n215-114-8\n1303-00-0\nTributyltin compounds, with the exception of those specified elsewhere in this Annex\n050-008-00-3\n—\n—\n1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear\n607-710-00-5\n271-093-5\n68515-50-4\nimidazole\n613-319-00-0\n206-019-2\n288-32-4\nbisphenol A; 4,4′-isopropylidenediphenol\n604-030-00-0\n201-245-8\n80-05-7\nphenol, dodecyl-, branched; [1]\nphenol, 2-dodecyl-, branched; [2]\nphenol, 3-dodecyl-, branched; [3]\nphenol, 4-dodecyl-, branched; [4]\nphenol, (tetrapropenyl) derivatives [5]\n604-092-00-9\n310-154-3 [1]\n- [2]\n- [3]\n- [4]\n- [5]\n121158-58-5 [1]\n- [2]\n- [3]\n210555-94-5 [4]\n74499-35-7 [5]\nchlorophacinone (ISO);2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione\n606-014-00-9\n223-003-0\n3691-35-8\ncoumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin\n607-059-00-7\n227-424-0\n5836-29-3\ndifenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin\n607-157-00-X\n259-978-4\n56073-07-5\nflocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin\n607-375-00-5\n421-960-0\n90035-08-8\ndisodium octaborate anhydrous; [1]\ndisodium octaborate tetrahydrate [2]\n005-020-00-3\n234-541-0 [1]\n234-541-0 [2]\n12008-41-2 [1]\n12280-03-4 [2]\nbromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one\n607-716-00-8\n249-205-9\n28772-56-7\ndifethialone (ISO);\n3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one\n607-717-00-3\n—\n104653-34-1\nperfluorononan-1-oic acid [1]\nand its sodium [2]\nand ammonium [3] salts\n607-718-00-9\n206-801-3 [1]\n- [2]\n- [3]\n375-95-1 [1]\n21049-39-8 [2]\n4149-60-4 [3]\ndicyclohexyl phthalate\n607-719-00-4\n201-545-9\n84-61-7\ntriflumizole (ISO);\n(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine\n612-289-00-6\n—\n68694-11-1\n’\n(b) the entry relating to flumioxazin (ISO); N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl)—2,H 1,4-benzoxazin-6-yl) cyclohex-1-ene-1,2dicarboxamide is replaced by the following entry:\n‘\nflumioxazin (ISO); 2-[7-fluoro-3-oxo-4- (prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3 (2H)-dione\n613-166-00-X\n—\n103361-09-7\n’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2017/1510/annex",
    "retrieved_at": "2026-11-01T14:44:35.851627+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}